Skip to main content
ReproCELL Incorporated logo

ReproCELL Incorporated — Investor Relations & Filings

Ticker · 4978 ISIN · JP3974770004 LEI · 529900NM7KR32GGRSU46 T Professional, scientific and technical activities
Open in API
Filings indexed 62 across all filing types
Latest filing 2023-11-10 Interim / Quarterly Rep…
Country JP Japan
Listing T 4978

About ReproCELL Incorporated

https://www.reprocell.com/

ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.

Recent filings

Filing Released Lang Actions
四半期報告書－第22期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a '第２四半期報告書' (Quarterly Report) for the company '株式会社リプロセル' (ReproCELL Incorporated) covering the period from July 1, 2023, to September 30, 2023. It contains detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of an Interim/Quarterly Report (IR). Q2 2024
2023-11-10 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan, which accompanies a Quarterly Report (Second Quarter). Since the document is a formal regulatory filing confirming the accuracy of the quarterly report and is submitted to the Kanto Local Finance Bureau, it falls under the category of Regulatory Filings (RNS) as it is a specific regulatory compliance document rather than the quarterly report itself or a simple announcement.
2023-11-10 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan. This is a mandatory internal control certification that accompanies a Quarterly Report (Shihanki Hokokusho). Since the document is a formal regulatory filing confirming the accuracy of the quarterly report and is not the quarterly report itself, it falls under the category of Regulatory Filings (RNS).
2023-08-10 Japanese
四半期報告書－第22期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a '第１四半期報告書' (First Quarter Report) filed by ReproCELL Incorporated. It contains detailed financial statements, management analysis (MD&A), and information on business operations for the period from April 1, 2023, to June 30, 2023. It is a comprehensive quarterly financial report, not an announcement or a summary, and thus fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2023-08-10 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2023
2023-06-27 Japanese
内部統制報告書－第21期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. This type of regulatory filing, which is a mandatory disclosure separate from the full Annual Report (10-K) or Audit Report (AR), falls under the 'Regulatory Filings' category as it is a specific compliance document required by Japanese financial regulators.
2023-06-27 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.